58 results about "Immunoglobulin G" patented technology

The invention relates to an aptamer specifically combined with beta-lactoglobulin and application of the aptamer, and belongs to the technical field of biological detection. According to the aptamer and the preparation method thereof, a binding domain base, participating in recognition, of the aptamer is predicted through molecular docking firstly, then the binding domain base is subjected to directional mutation, the aptamer with the recognition performance improved is obtained, the affinity of the aptamer to beta-lactoglobulin is 10.6 nM, and the aptamer has no recognition capacity on alpha-lactalbumin, casein, bovine serum albumin, immune globulin G, lactose and the like and can be used for preparing the aptamer with the recognition performance improved. Therefore, the aptamer disclosed by the invention has good sensitivity and specificity on the beta-lactoglobulin. On the basis, a fluorescence polarization method is directly constructed by utilizing the characteristic that the beta-lactoglobulin is a biomacromolecule, when the beta-lactoglobulin exists, an aptamer marked by a fluorophore FAM recognizes the beta-lactoglobulin to form an aptamer beta-lactoglobulin compound, and the fluorescence polarization value is relatively large, so that the beta-lactoglobulin compound can be used for identifying the beta-lactoglobulin. Therefore, the specific detection of the low-concentration beta-lactoglobulin is realized.

The present application relates to the field of livestock breeding technology, and discloses a molecular marker related to the level of natural immunoglobulin G antibody in chicken plasma and application thereof.The molecular marker related to the level of natural immunoglobulin G antibody in chicken plasma is the 251th nucleotide in SEQ ID NO:1, and the polymorphic form is G or A.The SNP molecular marker related to the level of natural immunoglobulin G antibody in chicken plasma provided by the present application can be used to select the level of natural immunoglobulin G antibody in chicken plasma at the genetic level, directly screen the level of natural immunoglobulin G antibody in chicken plasma from the root source, accurately grasp the genetic information, effectively avoid the disadvantages of traditional methods, significantly improve the efficiency and accuracy of selection, and can be applied to chicken breeding practice on a large scale, and promote the development of the industry.

The invention discloses an application of a biomarker in evaluating the risk of progressing from autoimmune hepatitis to cirrhosis. The biomarker comprises immune globulin G, and / or an antinuclear antibody, and / or aspartate aminotransferase and alanine aminotransferase. Independent predictive factor indexes of the liver cirrhosis risk of an autoimmune hepatitis patient in the biomarker are as follows: an antinuclear antibody ANA index: log2ANA is greater than or equal to 1.62; the AAR index of the ratio of aspartate aminotransferase to alanine aminotransferase is as follows: AAR is greater than or equal to 1.62; the immune globulin G, namely the IgG index, is greater than or equal to 30.3 g / L. The problems that in the prior art, an AIH risk model does not take cirrhosis as the outcome, visual presentation is lacked, prediction efficiency is insufficient, and clinical early-stage accurate risk layering and diagnosis and treatment decision requirements are difficult to meet are solved.

This invention provides a bovine colostrum IgG nutritional supplement gummies and their preparation method, belonging to the field of functional food technology. The bovine colostrum IgG nutritional supplement gummies of this invention, through precise formulation of specific components, effectively improve the dispersion uniformity of whole-fat bovine colostrum freeze-dried powder in the gummy base, significantly retaining the activity of immunoglobulin G, giving the product a stable texture and good taste; further, combined with a special process adapted to the formula, high yield and high raw material utilization are achieved in industrial production. This product combines immune nutritional supplementation with convenient consumption, making it suitable for people of all ages and possessing good market application prospects.

This invention relates to the fields of biomedical technology and biological model construction technology, and discloses an ANCA-associated vasculitis glomerular endothelial cell injury model, its construction method and application, and the application of BACH1 inhibitors. The method includes: (1) activating neutrophils sequentially with tumor necrosis factor α and immunoglobulin G to obtain a culture medium containing activated neutrophils; wherein the immunoglobulin G is immunoglobulin G isolated and purified from the plasma of patients with ANCA-associated vasculitis; (2) co-culturing the culture medium containing activated neutrophils with human glomerular endothelial cells to obtain the cell injury model. The cell injury model provided by this invention can verify the role of neutrophil adhesion characteristics in endothelial cell injury, and at the same time, the cell injury model can better simulate the immune microenvironment of ANCA-associated vasculitis glomerular endothelial cells in vivo.

The present disclosure relates to a method for separating and obtaining a target protein-enriched solution, such as immunoglobulin G (IgG), and a plurality of target protein-depleted fractions from a protein mixture, such as plasma or fractions thereof, using continuous chromatography. The present disclosure also relates to a continuous chromatography system for separating a target protein from a protein mixture, a formulation of its purified product and uses.

The application relates to the field of biological medicine, and particularly discloses application of saliva TP17, TP47 and TP15 specific antibodies in preparation of an auxiliary diagnostic product for neurosyphilis. Based on specific antibody immunoglobulin G (IgG) of Treponema pallidum in saliva, combined detection of saliva TP17 / IgG, TP47 / IgG and TP15 / IgG outputs a risk value of neurosyphilis of a subject, or a four combined Logistic regression discriminant model is constructed by combining serum TRUST titers, and the subject is stratified into a low-risk or high-risk group based on a preset judgment threshold, so that the comprehensive recognition capability for neurosyphilis is improved. The saliva is used as a detection sample, and the application has the advantages of non-invasiveness, convenience, easy popularization, repeatable collection and the like, and can be used for early screening, auxiliary diagnosis and clinical path management of neurosyphilis.

Provided herein are engineered fusion proteins comprising ApoM (e.g., human or murine ApoM) fused to a constant region (Fc) of a immunoglobulin G (IgG, e.g., human IgG or murine IgG). In some embodiments, the ApoM-Fc fusion protein further comprises a signal peptide (e.g., IL-2 signal peptide) fused to the ApoM, allowing the fusion protein to be secreted once expressed recombinantly. Methods of using the ApoM-Fc fusion protein or the sponge variants in the treatment of various diseases or disorders are provided.

The utility model discloses a kit for ultra-sensitive detection of a PLA2R-IgG (Immunoglobulin G) antibody. The kit comprises a kit body, and a box cover door is arranged on the front side of the kit body and hinged to one end of the kit body; a foldable handle is arranged on the box body; rotary connecting pieces are fixedly mounted on the outer surfaces of the left and right sides of the box body; the two ends of the foldable handle are rotatably and movably connected with the box body through rotary connecting pieces respectively; a sliding rail with a groove is fixedly mounted at each of the upper part and the bottom part of the inner walls of the left side and the right side of the box body, and the sliding rail at the upper part is connected with the transverse box; a rectangular positioning groove capable of placing a polystyrene pore plate is formed in the transverse box; the bottom slide rail is connected with the bottom box; and the bottom box is provided with a circular positioning hole groove for placing a reagent bottle for containing a reagent or a standard substance and a rectangular positioning hole groove for placing an ice bag. By arranging the sliding rail, the transverse box, the bottom box, the positioning hole groove, the foldable handle and the like, the purpose of improving convenience and stability in the storage and transfer process is achieved.

Provided herein are compounds, including compounds of any of the formulae described herein (e.g., Formula (I'), Formula (I), Formula (II)), and pharmaceutically acceptable salts thereof. Compounds provided herein are capable of covalently binding to and inhibiting neonatal fragment crystallizable receptor (FcRn) proteins and are therefore useful in the treatment and / or prevention of various diseases, including conditions associated with FcRn activity and / or immunoglobulin G (IgG) autoantibody levels in a subject.

The present application belongs to the field of clinical medicine, and particularly relates to a method for establishing an esophageal cancer auxiliary diagnosis model based on immunoglobulin G Fc segment N-glycosyl in serum and application thereof. The biomarker on which the esophageal cancer auxiliary diagnosis model provided by the present application is based is immunoglobulin G Fc segment N-glycosyl GP10, GP11, GP14, GP17 and GP23. The diagnosis model provided by the present application is constructed based on the level of five initial immunoglobulin G N-glycosyl in serum, and has the advantages of simplicity, convenient calculation and easy judgment. The model has high accuracy, high sensitivity and strong specificity for esophageal cancer diagnosis, and is much higher than the diagnosis of the conventional cancer markers CEA and CA199. The esophageal cancer diagnosis model constructed by the present application provides an effective, reliable and convenient method for the clinical diagnosis of gastrointestinal health, and has good auxiliary diagnosis value for gastrointestinal health.

To provide methods and compositions (including compositions of engineered / synthetic binding agents) for enhancing agglutination, enchainment and / or muco-trapping of a target, i.e., reducing the fraction of target entities that could permeate through mucus, including pathogens and sperm.SOLUTION: Provided are synthetic binding agents for reducing the fraction of targets that can permeate through mucus and / or freely divide, and methods of reducing mucosal permeation and / or free division of a target using these synthetic binding agents. The synthetic binding agent comprises a human or humanized Immunoglobulin G (IgG) having a pair of Fab domains, and enhances agglutination of the target in the subject's mucus to reduce the mobility of the target to less than about 50% relative to its native mobility in mucus.SELECTED DRAWING: Figure 1A

The invention relates to the field of in-vitro immunodiagnosis detection, in particular to an IgG antibody of mumps virus, a recombinant IgM antibody and application. Wherein the IgG antibody comprises a heavy chain constant region, a light chain constant region, and a heavy chain variable region and a light chain variable region of the IgG monoclonal antibody which is specifically combined with the mumps virus, and the IgG monoclonal antibody is of a mouse source or a rabbit source. According to the present invention, the IgG antibody is modified to obtain the recombinant IgM antibody, and the IgG antibody and the recombinant IgM antibody are not only suitable for the chemiluminescence method, but also show the expected sensitivity amplification factor in other immunological detection methods, such that the low-abundance detection of the specifically bound mumps virus can be easily achieved.

The present disclosure is related to chimeric antigen receptors (CARs) comprising Immunoglobulin G (IgG) derived spacers, e.g., a human IgG hinge and a human IgG Fc derived CAR spacer. IgGl derived spacers confer improved properties to the CARs, e.g., increased cytokine release with respect to CARs not comprising IgG derived spacers. Also provided are cells expressing CARs comprising IgG derived spacers regions and methods to use the CARs to treat diseases or disorders, e.g., cancer.

The present invention relates to a method and system for extracting proteins from precipitates, particularly recombinant and / or plasma derived proteins including immunoglobulins (Ig) such as immunoglobulin G (IgG).

The invention provides an IgG (immunoglobulin G) binding type immune activator protein as well as a preparation method and application thereof, and belongs to the technical field of medicines. It is found for the first time that after three Fab binding peptides CFab and N215 are fused, the N215 can be endowed with the IgG antibody binding capacity, the obtained fusion protein N215-CFab3 and the IgG antibody can form a stable compound, and the compound retains the functions of the N215 and the antibody, can mediate binding of the N215 to target cells, remarkably prolongs the half-life period of the N215, promotes proliferation of T and NK cells, and has the advantages of being capable of achieving the purpose of improving the immunogenicity of the N215 and improving the immunogenicity of the N215. The remarkably enhanced in-vivo anti-tumor effect is exerted. A compound formed by the fusion protein N215-CFab3 and an IgG antibody can be used as an immune activator, and has a wide application prospect in immunotherapy of diseases such as tumors and infection.

FIELD: clinical gastroenterology.SUBSTANCE: intended to predict the risk of relapse of autoimmune hepatitis after discontinuation of immunosuppressive therapy. The patient undergoes a clinical and biochemical examination and the relapse risk probability index is determined using the formula: PI RR = –0.394×(IGA≥ 9) + 1.252×(AT) + 0.915×(a-SLA / LP) + 0.555×(a-LKM1) – 0.692×(IgG norm) + 0.316×(obesity), where PI RR is the prognostic index of recurrence risk; HAI is the histological activity index of more than 9 according to Knodell (binary indicator: HAI ≥ 9 corresponds to the multiplier “1”; HAI < 9 corresponds to the multiplier “0”); AB – the presence of autoantibodies (binary indicator: detection of at least 1 corresponds to the multiplier “1”; absence of autoantibodies corresponds to the multiplier “0”); a-SLA / LP – antibodies to soluble liver / kidney antigen (binary indicator: presence – corresponds to the multiplier “1”; absence – corresponds to the multiplier “0”); a-LKM1 – antibodies to liver and pancreas microsomes (binary indicator: presence corresponds to the multiplier “1”; absence corresponds to the multiplier “0”); IgG – immunoglobulin G (binary indicator: normal Ig G level corresponds to the multiplier “1”; elevated IgG level corresponds to the multiplier “0”); obesity (BMI ≥ 30) – (binary indicator: presence of BMI ≥ 30 corresponds to a multiplier of “1”; BMI < 30 corresponds to the multiplier “0”). With the value of PI RR < 0.93 – low probability of relapse, PI RR > 0.93 – high probability of relapse.EFFECT: increased accuracy in predicting the risk of recurrence of autoimmune hepatitis after discontinuation of immunosuppressive therapy.1 cl, 2 ex

The present invention features fusion proteins comprising an immunoglobulin G-degrading enzyme domain and an albumin binding domain. The albumin binding domain can bind to human serum albumin and can be useful, for example, for increasing the half-life of the immunoglobulin G-degrading enzyme domain in a subject. Uses of the fusion protein include treatment reducing a potential host immune response to an administered treatment such as those involving a viral vector, or involving a tissue or organ transplant; treating an adverse IgG immune response; and treating an autoimmune disease or disorder.

Disclosed herein are methods for treating patients who may develop or have pre-existing neutralizing gene therapy antibodies by administering a protease that cleaves peptide bonds present in immunoglobulins or by administering a glycosidase that cleaves carbohydrate residues present in immunoglobulins, or other similar enzyme cleavage of immunoglobulins in vivo. Also disclosed are methods for using IdeS and other immunoglobulin G degrading enzyme polypeptides for gene therapy treatment of a disease in a patient in need thereof.

Provided are methods of treating rheumatoid arthritis comprising administering to a subject in need of such treatment a therapeutically effective amount of an immunoglobulin G degrading agent and an anti-arthritis agent. Also provided are pharmaceutical compositions comprising an immunoglobulin G degrading agent and an anti-arthritic agent.

The invention discloses a neutralizing antibody THC4677 for neutralizing SARS-CoV-2 in a broad spectrum and an application of the neutralizing antibody THC4677. The invention provides an IgG (Immunoglobulin G) antibody (named as THC4677 antibody) of spike protein specifically combined with SARS-CoV-2. The IgG antibody consists of a light chain and a heavy chain, cDR1, CDR2 and CDR3 in a heavy chain variable region in the heavy chain are sequentially as shown in 26th to 33rd sites, 51st to 58th sites and 97th to 111th sites in SEQ ID NO: 1; cDR1, CDR2 and CDR3 in a light chain variable region in the light chain are sequentially shown as the 27 to 38 , the 56 to 58 and the 95 to 104 in SEQ ID NO: 4. The THC4677 antibody has the effect of neutralizing the SARS-CoV-2 in a broad spectrum, and has an application value in prevention and control of the novel coronavirus.

The invention discloses a method for preparing active thermosensitive protein in fresh milk through continuous separation, and belongs to the technical field of lactoprotein separation. According to the method, efficient separation of lactoferrin, immunoglobulin G, alpha-lactalbumin and beta-lactoglobulin is realized through the steps of optimization pretreatment, primary membrane separation, continuous chromatography, purification, refining and the like. In the pretreatment stage, casein is removed by adjusting the pH to a casein isoelectric point, and whey protein is stabilized by combining sodium citrate; performing primary membrane separation to remove macromolecular impurities; the continuous ion exchange chromatography realizes synchronous separation of four proteins through gradient elution; and finally, performing ultrafiltration concentration and freeze drying to obtain a finished product. The purity of the four proteins separated by the method reaches 83%-86%, and the recovery rate is 76%-80%. Compared with a traditional method, protein denaturation is reduced through proper temperature control and sodium citrate pretreatment, the production efficiency is improved through continuous chromatography, and the method is suitable for continuously preparing the active milk protein and has high economic value and application prospects.

Described herein are heteromultimeric proteins comprising at least two different polypeptide chains. The polypeptides may comprise Cε3 domain and / or Cε4 domain derived from an immunoglobulin E, and a Cγ2 and / or a Cγ3 domain derived from an immunoglobulin G. The two polypeptide chains may preferentially heterodimerize to promote formation of the heteromultimer. The two polypeptide chains may bind to two different target molecules, e.g. a cancer antigen and a T cell antigen.

The present invention relates to a method and system for extracting proteins, in particular recombinant and / or plasma-derived proteins, including immunoglobulins (Ig), such as immunoglobulin G (IgG), from precipitate.

The invention discloses an MOG-IgG (Metal Organic Glycol-Immunoglobulin G) detection method based on a specific MOG subtype combined stably transfected cell. Two protein subtypes of MOG-alpha1 and MOG-beta1 are mixed and expressed in a 293T cell according to a ratio of 3: 1 to obtain a 293T-MOG-alpha1 + beta1 monoclonal stably transfected cell, and then a cytology-based determination (CBA) method is constructed on the basis of the monoclonal stably transfected cell and is used for detecting MOG-IgG. When the method is used for clinical serum MOG-IgG detection, the specificity is high, the sensitivity is high, the experimental result repeatability is good, the stably transfected cell strain can be stably subcultured, the consistency and the stability of the detection result are ensured, the detection efficiency is improved, and the occurrence probability of false positive and false negative is reduced.

The invention relates to the field of microbial culture, discloses a culture method for promoting growth of mucus type pseudomonas aeruginosa by using IgG, and belongs to the technical field of microbial culture. According to the method, a specific improved system is constructed aiming at the technical problems that mucus type pseudomonas aeruginosa with the genotype of ST270 is too long in growth retardation period and extremely slow in proliferation in a conventional LB or TSB culture medium. The method comprises the following specific steps: preparing a basic liquid culture medium and sterilizing; non-thermally inactivated immunoglobulin G (IgG) is added in a sterile manner, so that the final concentration of the non-thermally inactivated immunoglobulin G (IgG) is in a range of 5.0 mu g / mL to 5.0 mg / mL; and inoculating a target strain and then carrying out shake culture at 37 DEG C. By utilizing the modification effect of IgG molecules on the mucus layer on the surface of the thallus, physical steric hindrance or metabolic inhibition caused by an extracellular matrix is effectively overcome, the growth adaptation period is remarkably shortened, the biomass of the thallus is greatly improved, and rapid amplification and phenotype recovery of the rare strains difficult to culture are successfully realized.

The invention relates to a tumor-derived IgG (immunoglobulin G) antibody coupled human recombinant ferritin loaded CpG nano tumor vaccine. The nano tumor vaccine comprises a human recombinant ferritin core-shell structure, a tumor-derived IgG antibody is coupled to the surface of the human recombinant ferritin core-shell structure, and CpG is carried on the core of the human recombinant ferritin core-shell structure. The invention also relates to application of the nano tumor vaccine in treatment of melanoma.

The present application relates to the field of food technology, and specifically discloses a composition for reducing gastroesophageal reflux in individuals, a preparation method and application thereof. The composition for reducing gastroesophageal reflux in individuals comprises lactadherin, medium-long chain triglyceride, human milk oligosaccharide and immunoglobulin G. The present application constructs a multi-target synergistic intervention mechanism combining physical protection, secretion regulation and tissue repair through the compounding of four core components, which can comprehensively block the occurrence and development of gastroesophageal reflux. Lactadherin constructs a physical barrier to reduce the risk of reflux dynamics from the source; MLCT precisely regulates gastric acid secretion, reducing chemical stimulation; HMO compound IgG strengthens the mucosal immune barrier and promotes damage repair. The above composition is applied to products for reducing gastroesophageal reflux in individuals, and multi-target synergistic effect is achieved, realizing the whole-chain closed-loop intervention from prevention, relief to repair, and significantly improving the clinical improvement effect.

Provided herein are cyclic peptides capable of binding to and inhibiting neonatal fragment crystallizable receptor (FcRn) proteins, and methods of using the same for the treatment and / or prevention of various diseases, including conditions associated with FcRn activity and / or immunoglobulin G (IgG) autoantibody levels in a subject.

The present disclosure relates to a method for purifying an immunoglobulin degrading enzyme (IdeS) from Streptococcus pyogenes, preferably to a method for removing IdeS charge variants and IdeS obtainable from said method.